- Home
- WBX vs LXEO Comparison
WBX vs LXEO Comparison
Compare WBX & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- LXEO
- Stock Information
- Founded
- WBX 2015
- LXEO 2017
- Country
- WBX Spain
- LXEO United States
- Employees
- WBX N/A
- LXEO N/A
- Industry
- WBX Industrial Specialties
- LXEO
- Sector
- WBX Consumer Discretionary
- LXEO
- Exchange
- WBX Nasdaq
- LXEO Nasdaq
- Market Cap
- WBX 85.1M
- LXEO 93.9M
- IPO Year
- WBX N/A
- LXEO 2023
- Fundamental
- Price
- WBX $5.93
- LXEO $4.36
- Analyst Decision
- WBX Buy
- LXEO Strong Buy
- Analyst Count
- WBX 3
- LXEO 5
- Target Price
- WBX $14.33
- LXEO $16.60
- AVG Volume (30 Days)
- WBX 18.7K
- LXEO 468.4K
- Earning Date
- WBX 07-31-2025
- LXEO 08-11-2025
- Dividend Yield
- WBX N/A
- LXEO N/A
- EPS Growth
- WBX N/A
- LXEO N/A
- EPS
- WBX N/A
- LXEO N/A
- Revenue
- WBX $171,352,140.00
- LXEO N/A
- Revenue This Year
- WBX N/A
- LXEO N/A
- Revenue Next Year
- WBX $44.10
- LXEO N/A
- P/E Ratio
- WBX N/A
- LXEO N/A
- Revenue Growth
- WBX 3.75
- LXEO N/A
- 52 Week Low
- WBX $4.60
- LXEO $1.45
- 52 Week High
- WBX $32.80
- LXEO $13.63
- Technical
- Relative Strength Index (RSI)
- WBX 83.14
- LXEO 53.98
- Support Level
- WBX $5.92
- LXEO $4.07
- Resistance Level
- WBX $6.25
- LXEO $4.38
- Average True Range (ATR)
- WBX 0.26
- LXEO 0.29
- MACD
- WBX 0.20
- LXEO -0.05
- Stochastic Oscillator
- WBX 91.95
- LXEO 39.36
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.